A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience
Junichiro Watanabe, Mitsue Saito, Yoshiya Horimoto, Shogo Nakamoto
Topics & Concepts
EribulinMedicineInternal medicineOncologyHazard ratioMetastatic breast cancerTrastuzumabBreast cancerCancerGastroenterologyConfidence intervalImmune cells in cancerCancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies